Flavio Mavignier Cárcano

Learn More
PURPOSE Orteronel (TAK-700) is an investigational, nonsteroidal, reversible, selective 17,20-lyase inhibitor. This study examined orteronel in patients with metastatic castration-resistant prostate(More)
PURPOSE This study identifies the personal and professional profiles of researchers with a greater potential to publish high-impact academic articles. METHOD The study involved conducting an(More)
2559 Background: Randomized controlled trials (RCT) provide the most reliable evidence about therapeutic interventions. However, RCTs are still in risk of some bias, like assessment bias. In order to(More)
Prostate cancer (PCa) is the most commonly diagnosed neoplasm and the second leading cause of cancer-related deaths in men. Acquisition of resistance to conventional therapy is a major problem for(More)
e17568 Background: Liver metastasis (mets) from breast cancer is typically associated with poor prognosis. GC is a good option, since patients (pts) have often failed anthracycline and taxane therapy(More)